



(86) Date de dépôt PCT/PCT Filing Date: 2019/10/24
(87) Date publication PCT/PCT Publication Date: 2020/07/02
(45) Date de délivrance/Issue Date: 2023/10/31
(85) Entrée phase nationale/National Entry: 2021/06/23
(86) N° demande PCT/PCT Application No.: EP 2019/079029
(87) N° publication PCT/PCT Publication No.: 2020/135940
(30) Priorité/Priority: 2018/12/28 (EP18425109.8)

(51) Cl.Int./Int.Cl. *A61K 9/00* (2006.01),
A61K 9/127 (2006.01)
(72) Inventeurs/Inventors:
LAMBERT, ROLF, CH;
CAVALLO, GIOVANNI, IT
(73) Propriétaire/Owner:
DR. ROLF LAMBERT PHARMA-CONSULTING GMBH,
CH
(74) Agent: BERESKIN & PARR LLP/S.E.N.C.R.L.,S.R.L.

(54) Titre : SOLUTION DE GOUTTES POUR LES YEUX EN LIPOSOME ET UTILISATIONS CONNEXES POUR LE TRAITEMENT DU SYNDROME DES YEUX SECS
(54) Title: LIPOSOMIAL EYE DROPS SOLUTION AND USES THEREOF FOR THE TREATMENT OF DRY EYE SYNDROME

(57) Abrégé/Abstract:

Ophthalmic formulations and uses thereof, for the treatment of dry eye syndrome, wherein an eye drops solution is composed of liposomes built with non hydrogenated phospholipids containing Linseed oil, Vitamin A Palmitate, Vitamin E TPGS and in water phase Vitamin B12 and Pycnogenol. The presence of Pycnogenols increases the antioxidant capacity in external water phase and the presence of Vitamin E TPGS increases the antioxidant effect on lipophilic phase of liposomes. The presence of Vitamin E TPGS, inside the liposomes, combined with the presence of Pycnogenol and Vitamin B12 outside the liposomes, have a protective effect (shield) against UV A/UVB rays. It is further object of the invention, a liposomal eyes drops solution as above described, containing a specific and peculiar system composed of 2-Amino-2 (hydroxymethyl) propane-1,3-diol, that act as salt forming agent for Pycnogenol (sparkly water soluble) and borate buffer, in order to improve the filterability of liposomes and have a satisfying filtration procedure to sterilize liposomal eyes drops only by filtration at 0.2 micron, avoiding the steam sterilization that would destroy the other components and liposomes structure.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property

Organization

International Bureau

(43) International Publication Date

02 July 2020 (02.07.2020)



(10) International Publication Number

WO 2020/135940 A1

(51) International Patent Classification:

A61K 9/00 (2006.01)*A61K 9/127* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/EP2019/079029

Published:

— with international search report (Art. 21(3))

(22) International Filing Date:

24 October 2019 (24.10.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

18425109.8

28 December 2018 (28.12.2018) EP

(71) Applicant: **DR. ROLF LAMBERT PHAR-MA-CONSULTING GMBH** [CH/CH]; Kerbelring 27, 9230 Flawil (CH).

(72) Inventors: **LAMBERT, Rolf**, Kerbelring 27, 9230 Flawil (CH). **CAVALLO, Giovanni**, Via delle Tartane, 45, 00122 Lido di Ostia (ROME) (IT).

(74) Agent: **SARPI, Maurizio** et al.; Studio Ferrario Srl, Via Collina, 36, 00187 Rome (IT).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: LIPOSOMIAL EYE DROPS SOLUTION AND USES THEREOF FOR THE TREATMENT OF DRY EYE SYNDROME

(57) Abstract: Ophthalmic formulations and uses thereof, for the treatment of dry eye syndrome, wherein an eye drops solution is composed of liposomes built with non hydrogenated phospholipids containing Linseed oil, Vitamin A Palmitate, Vitamin E TPGS and in water phase Vitamin B12 and Pycnogenol. The presence of Pycnogenols increases the antioxidant capacity in external water phase and the presence of Vitamin E TPGS increases the antioxidant effect on lipophilic phase of liposomes. The presence of Vitamin E TPGS, inside the liposomes, combined with the presence of Pycnogenol and Vitamin B12 outside the liposomes, have a protective effect (shield) against UV A/UVB rays. It is further object of the invention, a liposomal eyes drops solution as above described, containing a specific and peculiar system composed of 2-Amino-2 (hydroxymethyl) propane-1,3-diol, that act as salt forming agent for Pycnogenol (sparkly water soluble) and borate buffer, in order to improve the filterability of liposomes and have a satisfying filtration procedure to sterilize liposomal eyes drops only by filtration at 0.2 micron, avoiding the steam sterilization that would destroy the other components and liposomes structure.

**WO 2020/135940 A1**

**LIPOSOMIAL EYE DROPS SOLUTION AND USES THEREOF FOR THE
TREATMENT OF DRY EYE SYNDROME.**

DESCRIPTION

5 Summary of the invention

The present invention relates to ophthalmic formulations, kits and uses thereof, wherein an eye drops solution is composed of Liposomes built with non hydrogenated phospholipids containing Linseed oil,
10 Vitamin A Palmitate, Vitamin E TPGS and in water phase Vitamin B12 and Pycnogenol™.

The presence of Pycnogenols increases the antioxidant capacity in external water phase and the presence of Vitamin E TPGS increases the antioxidant
15 effect on lipophilic phase of liposomes.

The presence of Vitamin E TPGS, inside the liposomes, combined with the presence of Pycnogenol™ and Vitamin B12 outside the liposomes, have a protective effect (shield) against UV A/UVB rays.

20 It is further object of the invention, a liposomal eyes drops solution as above described, containing a specific and peculiar system composed of 2-Amino-2(hydroxymethyl) propane-1,3-diol, that act as salt forming agent for Pycnogenol™ (sparkly water soluble)
25 and borate buffer, in order to improve the filterability of liposomes and have a satisfying filtration procedure to sterilize liposomal eyes drops only by filtration at 0.2 micron, avoiding the steam sterilization that would destroy the other components
30 and liposomes structure.

Furthermore, the presence of 2-Amino
2(hydroxymethyl) propane-1,3-diol, that acts as salt
forming agent of Pycongenols, increases the protective
effect of such molecules and the filterability of the
5 solution.

State of the art

Dry eye syndrome is caused by a chronic lack of
sufficient lubrication and moisture on the surface of
the eye. Consequences of dry eyes range from subtle but
10 constant eye irritation to significant inflammation and
even scarring of the front surface of the eye.

Symptoms of dry eyes and dry eye syndrome include:

- Burning sensation Itchy eyes Aching sensations Heavy
eyes
- 15 - Fatigued eyes
- Sore eyes Dryness sensation
- Red eyes
- Photophobia(light sensitivity)
- Blurred vision
- 20 - Another common symptom is something called a
foreign body sensation – the feeling that grit or some
other object or material is "in" your eye.
- Watery eyes also can be a symptom of dry eye
syndrome.
- 25 - This is because dryness on the eye's surface
sometimes will over-stimulate production of the watery
component of your tears as a protective mechanism.
- But this "reflex tearing" does not stay on the eye
long enough to correct the underlying dry eye condition.
- 30 In addition to these symptoms, dry eyes can cause

inflammation and (sometimes permanent) damage to the surface of the eye.

What Causes Dry Eye Syndrome?

Dry eyes are caused by a lack of adequate tears.

5 Your tears are a complex mixture of water, fatty oils and mucus. This mixture helps make the surface of your eyes smooth and clear, and it helps protect your eyes from infection.

For some people, the cause of dry eyes is
10 decreased tear production. For others it's increased tear evaporation and an imbalance in the makeup of your tears.

Decreased tear production

Dry eyes can occur when you're unable to produce
15 enough tears. The medical term for this condition is keratoconjunctivitis sicca. Common causes of decreased tear production include:

Aging

- Certain medical conditions, including diabetes,
20 rheumatoid arthritis, lupus, scleroderma, Sjogren's syndrome, thyroid disorders and vitamin A deficiency;
- Certain medications, including antihistamines, decongestants, hormone replacement therapy,
25 antidepressants, and drugs for high blood pressure, acne, birth control and Parkinson's disease;
- Laser eye surgery, though symptoms of dry eyes related to this procedure are usually temporary;
- Tear gland damage from inflammation or radiation;

An adequate and consistent layer of tears on the surface of the eye is essential to keep your eyes healthy, comfortable and seeing well.

- Tears bathe the eye's surface to keep it moist and
5 wash away dust, debris and microorganisms that could damage the cornea and lead to an eye infection.

- A normal tear film consists of three important components:

1. An oily (lipid) component
- 10 2. A watery (aqueous) component
3. A mucous-like (mucin) component

Aim of the invention

To try to solve or at least to reduce in part, the negative effects of dry eyes syndrome as above shortly
15 described the Applicant studied and developed a formulation in which had to be present component that:
have anti inflammatory action;
have antioxidant action ;
restore the oil layer on eye surface;
20 maintain moisture;
can be sterilized.

- Briefly, through different steps, the activity carried out by the Applicant allowed to define how to produce, at industrial scale, an eye drops solution
25 composed of Liposomes built with non hydrogenated phospholipids containing Linseed oil, Vitamin A Palmitate, Vitamin E TPGS, and in water phase Vitamin B12 and Pycnogenols.

- This liposomal eye drops solution has to be
30 sterilized by filtration at 0.2 micron, because the

steam sterilization (121 C for 15 minutes at 1 atm)
destroys all components of liposomes.

- To achieve such result the liposomal eyes drop
solution contains liposomes built with **non**
5 hydrogenated phospholipids containing Linseed Oil and
Vitamin A Palmitate and also Vitamin E TPGS that for
its specific structure improves the filterability of
liposomes, but this improvement it is not enough to
have a satisfactory filtration procedure, at least at
10 industrial scale, to sterilize liposomal eyes drops.
Such drawback is due to Pycnogenols presence in water
phase.

- To achieve such result the liposomal eyes drops
solution according to the invention contains a specific
15 and peculiar system composed of 2-Amino-
2(hydroxymethyl)propane-1,3-diol, that acts as salt
forming agent for Pycnogenols (sparkly water soluble),
and borate buffer.

- Surprisingly, said liposomal eyes drops solution
20 exerts a shield effect against UVA UVB rays (UVA 315-
400 nm - UVB 315 -280). Such unexpected property is
linked primarily to liposomes (plus Vitamin E TPGS) and
secondarily to Vitamin B12 and Pycnogenols in water
phase.

25 No documents of prior art, such as MARTA VICARIO-
DE-LA-TORRE ET AL in "Novel Nano-Liposome Formulation
for Dry Eyes with Components Similar to the Preocular
Tear Film", POLYMERS, vol. 10, no. 4, 11.04.2018, page
425, and CN 1850054 A, disclose an eye drops solution
30 for use in the treatment of dry eye syndrome, wherein
said solution comprises liposomes built with non

hydrogenated phospholipids containing Linseed oil, Vitamin A palmitate, Vitamine E TPGS, and in water phase, Vitamin B12 and pycnogenols.

5 We report below the different steps to reach the final solution according to the present invention.

The qualitative composition of the starting formulation is shown below.


10

Qualitative Starting Formula

Raw Material	CAS number
Phospholipid S80	8030-76-0
Linseed Oil	6217-54-5
Vitamin A palmitate	79-81-2
Hyaluronic sodium salt (1.5-1.7 MDa)	-
Boric Acid	10043-35-3
Sodium Tetraborate Decahydrate	1303-96-4
Sodium Chloride	7647-14-15
Distilled Water	-

- **Description and specific function of each ingredient:**

Phospholipis



1-hexadecanoyl-2-linoleoyl-sn-glycero-3-phosphocholine

15

- Given that the lipid layer has an important influence on the tear, understanding the structure of

this portion of the tear structure is critical. This thin layer of lipid, usually 50nm to 100nm, is not a single homogeneous layer. It is believed that there is a layer of polar lipids overlying the aqueous layer of the tears, and a second layer of non-polar, hydrophobic lipids facing the air.

- It is in this layer that phospholipids play an important role to stabilize the structure

- Phospholipids are the peculiar constituents of liposomes.

- Liposomes are composite structures made of phospholipids and may contain amounts of other molecules, such as in our case Linseed oil and Vitamin A Palmitate

- Then Liposomes formed by Phospholipids (Phosphatidylcholine) exert a specific function of carriers.

- In the other hand the liposomes when are on the surface of eyes deliver the molecules carried by them by a mechanism of fusion and in the meantime the phosphatidylcholine is delivered to the lipid layer that is so important for the functionality of eyes, (see Reference 3).

- Linseed Oil

- The linseed oil inhibits PGE2-, leukotriene-, histamine- and bradykinin-induced inflammation. The oil also inhibits arachidonic acid-induced inflammation, suggesting its capacity to inhibit both cyclooxygenase and lipoxygenase pathways of arachidonate metabolism.

- In tail immersion model, the oil raised the pain threshold to a lesser extent than morphine but showed


excellent peripherally acting, analgesic activity comparable to aspirin, against acetic acid-induced writhing in mouse. In typhoid paratyphoid A/B vaccine-induced pyrexia, the oil showed antipyretic activity
5 comparable to aspirin. The oil contains 57.38% alpha-linolenic acid.

- Dual inhibition of arachidonic acid metabolism, antihistaminic and antibradykinin activities of the oil could account for the biological activity and the
10 active principle could be alpha-linolenic acid an omega-3 (18:3, n-3) fatty acid. (Lipid modifier of eye surface with anti/inflammatory effect).

Linseed oil exerts also the function to reinforce lipophilic (oily) layer on surface of eye as that
15 could be destroyed by dry eyes syndrome (see Reference 1)

- Vitamin A Palmitate

- Retinyl Palmitate is a naturally-occurring phenyl analogue of retinol (vitamin A) with potential
20 antineoplastic and chemopreventive activities.




- As the most common form of vitamin A taken for dietary supplementation, retinyl palmitate binds to and
5 activates retinoid receptors, thereby inducing cell differentiation and decreasing cell proliferation. This agent also inhibits carcinogen-induced neoplastic transformation, induces apoptosis in some cancer cell types, and exhibits immunomodulatory properties.
10 (NCI04)

- The antioxidant activity of vitamin A and carotenoids is conferred by the hydrophobic chain of polyene units that can quench singlet oxygen, neutralize thiyl radicals and combine with and
15 stabilize peroxy radicals. In general, the longer the polyene chain, the greater the peroxy radical stabilizing ability. Because of their structures, vitamin A and carotenoids can autoxidize when O₂ tension increases, and thus are most effective
20 antioxidants at low oxygen tensions that are typical of physiological levels found in tissues. (eye surface)

- Reference 2

- The Vitamin A Palmitate acts as antioxidant, (0.690 V Redox potential), protecting the linseed oil,
25 this specific action is combined to capacity to form as well as Linseed oil an lipophilic layer on eye.

- Hyaluronic Acid sodium salt



Hyaluronic acid (HA; conjugate base hyaluronate), also called hyaluronan, is an anionic, nonsulfated glycosaminoglycan distributed widely throughout connective, epithelial, and neural tissues. It is unique among glycosaminoglycans in that it is nonsulfated, forms in the plasma membrane instead of the Golgi apparatus, and can be very large, with its molecular weight often reaching the millions. It is used very often in eyes drops formulation for eye dry syndrome , (see Reference 9).

On the basis of the preceding argumentations, it is developed a quantitative starting formulation for a lot of experimental tests as follows:

Quantitative Starting Formula A

Raw Material	%w/w	CAS number
Phospholipid S80	0.500	8030-76-0
Linseed Oil	0.050	6217-54-5
Vitamin A palmitate	0.010	79-81-2
Hyaluronic sodium salt (1.5-1.7 MDa)	0.150	-
Boric Acid	0.775	10043-35-3
Sodium Tetraborate Decahydrate	0.120	1303-96-4
Sodium Chloride	0.424	7647-14-15

Distilled Water	100	-
Sterile at 0,2 micron		- YES

-

- It is important to note that in order to obtain a formulation that could be a wide application on dry eyes syndrome

5 - the formulation has to be sterilized by filtration with a 0.2 micron filter: this procedure is compulsory because Linseed oil, Vitamin A Palmitate and Hyaluronic acid are not stable to sterilization at 121°C at 1 atm for 15 minutes.


10 - Also the Liposomal structure composed of not hydrogenated Phosphatidylcholine is ruined by such rude treatment

From this consideration the filterability of formulation becomes a limiting factor for industrial development of Product. The preliminary work using a prototype product (5.0 litres) showed that however, even the filtration is feasible, it is very long with the possible the filter clogging, due to the presence of oil phase (Linseed Oil and Vitamin A Palmitate) inside the liposomes structure with hyaluronic acid sodium salt outside in water solution

Second Improvement: Test of stability

In order to overcome this technical problem, the inventor following numerous tests to increase the stability (redox capacity) and specificity of above formulation containing Linseed Oil and Vitamin A Palmitate found that the better solution was surprisingly the addition of Vitamin E.

Vitamin E



5 α -tocopherol/Vitamin E

In fact, Vitamin E acts as a radical scavenger, delivering an H atom to free radicals. At 323 kJ/mol, the O-H bond in tocopherols is about 10% weaker than in
10 most other phenols

This weak bond allows the vitamin E to donate a hydrogen atom to the peroxyl radical and other free radicals, minimizing their damaging effect.

The thus generated tocopheryl radical is
15 relatively unreactive but revert to tocopherol by a redox reaction with a hydrogen donor such as vitamin C.

As it is fat-soluble, it is incorporated into cell membranes, which are protected from oxidative damage by vitamin E.

20 Thus, α -Tocopherol Vitamin E protects Vitamin A in eyes.

In other words, interactions between alpha-tocopherol (vitamin E) and all-trans retinol (Vitamin A) suppress lipid peroxidation using unilamellar
25 liposomal system of phosphatidylcholine from either egg or soybean. (see Reference 6)

Taking into account this result, the Applicant changed the formula as follows:

Formulation with Vitamin E - Formula B

Raw Material	%w/w	CAS number
Phospholipid S80	0.500	8030-76-0
Linseed Oil	0.050	6217-54-5
Vitamin A palmitate	0.010	79-81-2
Vitamin E Acetate	0.008	9002-96-4
Hyaluronic sodium salt (1.5-1.7 MDa)	0.150	-
Boric Acid	0.775	10043-35-3
Sodium Tetraborate Decahydrate	0.120	1303-96-4
Sodium Chloride	0.424	7647-14-15
Distilled Water	100	-

-

- The preliminary work using a prototype product (5 litres) of formula B (formulation with Vitamin E) showed that the filtration of such formula is enough easy, even if few difficulties occur during the filtration process, due to the presence of oil phase (Linseed Oil ,Vitamin A Palmitate and Vitamin E Acetate) inside the liposomes structure with hyaluronic acid sodium salt outside the liposomes.

10 **Third improvement**

To increase the stability and specificity of above formulation B containing Linseed Oil, Vitamin A Palimitate and Vitamin E Acetate we added to previous formulation the Pycnogenols extract assuming that should have antioxidant effect.

The Pycnogenols extract should exert, also, a shield effect against UV rays insult on ocular surface.

- **Pycnogenols extract**

It is combination of bioflavonoids from pine bark of French maritime pine and scavenges free radicals, with an anti inflammatory effects and promotes cellular health exerts is antioxidant effect in hydrophilic milieu.

- Between 65% and 75% of Pycnogenol™ are procyanidins comprising of catechin and epicatechin subunits with varying chain lengths. Other constituents are polyphenolic monomers, phenolic or cinnamic acids and their glycosides. As many studies indicate, pycnogenol™ components are highly bioavailable.

- Uniquely, pycnogenol™ displays greater biological effects as a mixture than its purified components do individually indicating that the components interact synergistically.

- Pycnogenol™ can protect the chain of lipid bilayer against oxidative damage to fatty acids.

- During the process of lipoperoxidation, free radicals react with polyunsaturated fatty acids first resulting in the formation of conjugated dienes from which peroxy radicals and hydroperoxides are formed in aerobic conditions.

- These products decrease the production of thiobarbituric acid-reactive substances (TBARS), indicating that the protective effect of PYC is due to its antioxidant activity.

- From the tests result that the antioxidant action of Pycnogenol™ in the proposed formulation B has a dual goals:

- protect eye surface from free radicals even in hydrophilic compartment,

- protect the no Hydrogetated phospholipids that are the building stones of liposomes and are carriers of Linseed Oil and Vitamin A Palmitate and Vitamin E Acetate. (see Reference 4)

5 Thus, we defined a new formulation with Pycnogenols extract as follows:

Formulation with Pycnogenols extract - Formula C

Raw Material	%w/w	CAS number
Phospholipid S80	0.500	8030-76-0
Linseed Oil inside liposomes	0.050	6217-54-5
Vitamin A palmitate inside liposomes	0.010	79-81-2
Vitamin E Acetate inside liposomes	0.008	9002-96-4
Pycnogenols outside liposomes	0.017	174882-69-0
Hyaluronic sodium salt (1.5-1.7 MDa) outside liposomes	0.150	-
Boric Acid	0.775	10043-35-3
Sodium Tetraborate Decahydrate	0.120	1303-96-4
Sodium Chloride	0.424	7647-14-15
Distilled Water	100	-
Steril at 0,2 micron		


10 - However the filtration test using a prototype product(5 liters of Formula C) showed that the Liposomes formulation in presence of Pycnogenols becomes not easily filterable at 0.2 micron.

15 - Moreover Picnogenols, before and after sterilization at 0.2 micron, do not appear perfectly solubilized and their color is Reddish;

- Furthermore the final product C looks with not well defined color with some "micro fines" dispersed on solution outside the liposomes.
- This means for the formulation C several critical points has to be solved like:
 - not clear, not limpid appearance
 - product stability/ sedimentation,
 - a poor shield effect of Pycnogenols against UVA/UVB rays because appear not completely soluble.
- In view of said unsatisfactory results, several formulations, below reported, have been prepared to overcome or at least to reduce, the critical points above indicated.

Improvement of Appearance: To mask the not well defined color of formulation C we added Vitamin B12 that have in water solution a strong Red Color.

- Vitamin B12



- It is well known that B12 deficiency is related with Neuropatic ocular pain, this pharmacological action is linked to chemical physical peculiarity of such Vitamin.

- The presence of Vitamin B12, that have a clear red color when solubilized in water, gives to the final product D a well defined Pink color, improving the visual appearance of the product. (see Reference 5)

5

Formulation with Vitamin B12 - Formula D

Raw Material	%w/w	CAS number
Phospholipid S80	0.500	8030-76-0
Linseed Oil in side liposomes	0.050	6217-54-5
Vitamin A palmitate in side liposomes	0.010	79-81-2
Vitamin E Acetate inside liposomes	0.008	9002-96-4
Pycnogenol™ outside liposomes	0.017	174882-69-0
Vitamin B12 out side liposomes	0.0035	68-19-19
Hyaluronic sodium salt (1.5-1.7 MDa) out side liposomes	0.150	-
Boric Acid	0.775	10043-35-3
Sodium Tetraborate Decahydrate	0.120	1303-96-4
Sodium Chloride	0.424	7647-14-15
Distilled Water	100	-
Steril at 0,2 micron		YES
Color		Frankly red

- The preliminary work using a prototype product (5 liters) showed that the filtration of such formula D is very difficult, due the presence of oil phase (Linseed Oil ,Vitamin A Palmitate and Vitamin E Acetate) inside the liposomes structure and hyaluronic acid sodium salt and Pycnogenols and Vitamin B12 outside in water phase.

- Instead, the appearance of final product is very good, its color is PINK, the presence of Pycnogenols (

10

15

microfines) masked by the strong PINK COLOR of Vitamin B12.

- , However, the formulation Critical Concerns:


1) Possible instability of formulation
5 (sedimentation of Pycnogenols microfines joined to not efficient shield effect against UV rays)

2) The difficulty to filtrate the formulation remain unsolved.

First Attempt to Improve Filtration Performance

10 To increase the filtration performance we substitute in above formulation Vitamin E acetate with VITAMIN E TPGS, this derivative of Vitamin E should improve the filterability of all composition saving antioxidant capacity, at least in water phase , by
15 increasing the solubility of Pycnogenols extract

Vitamin E TPGS



D- α -

tocopheryl polyethylene glycol succinate (Vitamin E
25 TPGS, or simply TPGS) is a water-soluble derivative of natural Vitamin E, which is formed by esterification of Vitamin E succinate with polyethylene glycol (PEG). As such, it has advantages of PEG and Vitamin E in application of various nanocarriers for drug delivery,
30 including extending the half-life of the drug in plasma and enhancing the cellular uptake of the drug.

TPGS has an amphiphilic structure of lipophilic alkyl tail and hydrophilic polar head with a hydrophilic/lipophilic balance (HLB) value of 13.2 and a relatively low critical micelle concentration (CMC) of 0.02% w/w, which make it to be an ideal molecular biomaterial in developing various drug delivery systems, including pro drugs, micelles, liposomes and nanoparticles, which would be able to realize sustained, controlled and targeted drug delivery as well as to overcome multidrug resistance (MDR) and to promote oral drug delivery as an inhibitor of P-glycoprotein (P-gp) (see Reference 7)

Formulation with Vitamin E TPGS outside Liposomes structure in water phase - Formula E

Raw Material	%w/w	CAS number
Phospholipid S80	0.500	8030-76-0
Linseed Oil inside liposomes	0.050	6217-54-5
Vitamin A palmitate inside liposomes	0.010	79-81-2
Vitamin B12 outside liposomes	0.0035	68-19-19
Pycnogenol™ outside liposomes	0.017	174882-69-0
Vitamin E TPGS outside liposomes	0.025	9002-96-4
Hyaluronic sodium salt (1.5-1.7 MDa) out side liposomes	0.150	-
Boric Acid	0.775	10043-35-3
Sodium Tetraborate Decahydrate	0.120	1303-96-4
Sodium Chloride	0.424	7647-14-15
Distilled Water	100	-

- The preliminary work using such prototype (5 liters), containing Vitamin ETPGS, outside the

liposomes showed that the filtration of such formula is feasible and easier respect to formulation with Vitamin E Acetate, even if the antioxidant power inside lipophilic phase clearly is diminished.

5 This improved filtration performance means that Vitamin E TPGS increases the Fluidity of all mixture composed by liposomes (containing Vitamin A Palmitate, Leenseed Oil) Vitamin B12 (freely soluble in water), Hyaluronic acid sodium salt (soluble in water).

10 The performance of filtration is almost good, (but not easy and complete), this improvement is due the Presence of Vitamin ETPGS in solution outside the liposomes, but some concerns on Pycnogenols still remain.

15 In order to improve the filterability of the liposomal solution, and maintain the antioxidant power on lipophilic phase, we added Vitamin E ETPGS inside the liposomal structure, obtaining surprisingly a further improvement of the filterability.

20

Last formulation E composed as below described

Raw Material	%w/w	Functions
Phospholipid S80	0.500	Building liposomes structure
Linseed Oil	0.050	Oil inside the liposomes Anti inflammatory action
Vitamin A palmitate	0.010	Oil inside the liposomes Antioxidant antiinflammatory action
Vitamin E TPGS inside liposomes	0.025	Anti oxidant and filtration

		performance improver
Pycnogenol™	0.017	Antioxidant, outside liposomes
Vitamin B12	0.0035	Anti neuropatic effect and masking color, outside liposomes
Hyaluronic sodium salt (1.5-1.7 MD) out side liposomes	0.150	Viscosity improver outside liposomes
Boric Acid	0.775	Buffer
Sodium Tetraborate Decahydrate	0.120	Buffer
Sodium Chloride	0.424	Osmotic modifier
Distilled Water	100	-
Sterile by filtration at 0,2 micron		YES

This improved filtration performance means that Vitamin E TPGS increases the fluidity of liposomes (containing Vitamin A Palmitate, Leenseed Oil), such

5 increased liposomal fluidity exerts a positive effect on filterability of all mixture composed liposomes and Vitamin B12 (freely soluble in water), Hyaluronic acid

sodium salt (soluble in water) and Pycnogenols that still remain not perfectly filterable


In few words this improvement is good but not enough to guaranty an easy and reliable sterilization
5 by filtration at 0.2 micron, at least at industrial scale, 100-200 litres each time.

- This difficulty pushed us to focus our attention on peculiar unexpected behavior of Pycnogenols extract.

- In fact Pycnogenol™ is declared soluble in water,
10 but the difficulties that we had on filtration at 0.2 micron indicate that this statement is not really true.


- Pycnogenol® contains the bioflavonoids as catechin, epicatechin and taxifolin as well as phenolcarbonic acids, such molecules are very weak acid
15 and are slightly soluble in water

- We report below the chemical structures of catechin, epicatechin and taxifolin:




20

Catechin



(-)-Epicatechin (2R,3R)



5 Taxifolin


The chemical structures above reported, referring at least to part of components of Pycnogenols mixture, indicate that such molecules, to be freely soluble in water have to be modified in Salts Forms.

10 To clarify this points we prepared the following solutions:

Pycnogenols 0.034 % in Water;

Pycnogenols 0.034 % in Decahydrate Borate solution (final pH 7.05);

15



SODIUM BORATE, DECAHYDRATE ,

20 and

Pycnogenols 0.034 % in Tris solution (final pH 7.1) .



Tris (2-Amino-2-(hydroxymethyl)propane-1,3-diol)

5

Pynogenol Tris buffer solution is RED.

Pynogenol Borate buffer solution is REDDISH.

10 Second Attempt to Improve Filtration Performance

To increase the filtration performance we added in above formulation Tris ((2-Amino-2(hydroxymethyl)propane-1,3-diol), to increase the solubility of Pynogenols extract.

15

Formulation with TRIS as salts forming agent: Formula F

Raw Material	%w/w	Functions
Phospholipid S80	0.500	Building liposomes structure
Linseed Oil	0.050	Oil inside the liposomes Anti inflammatory action
Vitamin A palmitate	0.010	Oil inside the liposomes Antioxidant anti inflammatory action
Vitamin E TPGS inside liposomes	0.025	Antioxidant and filtration performance improver
Pycnogenol™	0.017	Antioxidant, outside liposomes
Tris (2-Amino-2(hydroxymethyl)propane-1,3-diol	0.3-0.2	Buffering agent and salt forming agent
Vitamin B12	0.0035	Anti neuropatic effect and masking color
Hyaluronic sodium salt (1.5-1.7 MDa) out side liposomes	0.150	Viscosity improver
Boric Acid	0.775	Buffer

Sodium Tetraborate Decahydrate	0.060- 0,120	Buffer
Sodium Chloride	0.2- 0,15	Osmotic modifier
Distilled Water	100	-
Sterilization by filtration at 0.2 micron	Yes	Sterile
Ph	7,1-7.4	-
Osmolality mMOs/kg	275 290	-
Sterile at 0.2 micron		YES

-

- Last formulation composed,(formula F) as above described, can be sterilized by filtration with 0.2 micron filter: the performance of filtration is

5 Excellent .

- The improvement is due to the presence of Tris(2-Amino-2(hydroxymethyl)propane-1,3-diol) that reacting with Phenolic groups of catechin like molecules, produce salts (an ion pair) very soluble in water, (see

10 References 10 /11) .

- This improved filtration performance is then due to the combined effect of Vitamin E TPGS inside of liposomes, and Tris outside of liposomes.

Conclusions

15 The activity performed allow us to produce a Formulation, (Formula F) that could be a wide application on dry eyes syndrome because it contains components that:

have anti inflammatory action,

20 have antioxidant action,

Counteract Neuropatic Ocular Pain Restore the oil layer on eye surface,

Maintain moisture.

- The presence of Pycnogenols increases the antioxidant capacity in external water phase and the presence of Vitamin E TPGS increases the antioxidant effect on lipophilic phase of liposomes
- 5 - The activity performed allow us to produce a Formulation at industrial scale, with excellent filterability, that results are linked to specific presence of Vitamin E TPGS and addition of TRIS that exerts a peculiar function of solubilizing, (salt
10 forming) Pycnogenols

Further test: Protective effect against UVA/UVB rays

The presence of Vitamin E TPGS, inside the liposomes, combined with presence of Pycnogenols and
15 Vitamin B12, outside the liposomes, should have a Protective (shield) effect against UVA/UVB rays.

To evaluate such hypothesis, we irradiated for 15 minutes with UVA/UVB Lamp* several preparations, listed below containing Vitamin A Palmitate:

- 20 - Vitamin A Palmitate 0.010% Solution;
- Vitamin A Palmitate 0.010%, Vitamin E TPGS 0.025% inside Liposomes ;
- Vitamin A Palmitate 0.010%, Vitamin E TPGS 0.025% in Liposomes plus Pycnogenols 0.017% in water phase ;
- 25 - Vitamina A Palmitate 0.010%, Vitamin E TPGS 0.025% inside Liposomes plus Vitamin B12 0.0035% in water phase; and
- Vitamin A Palmitate 0.010% + Vitamina E TPGS 0.025% inside Liposomes plus Pycnogenol™ 0.017% + Vitamin
30 B12 0.0035% in water phase.

We measured the concentration of Vitamin A Palmitate before and after this treatment, the table 1 below summarizes the results obtained.

5

TABLE 1

	Vitamin A Palmitate % before UVA/UVB treatment	VitaminA Palmitate% after UVA/UVB treatment	Degradation %
Vitamin A Palmitate 0.010% Solution	0.0100 %	0.0020 %	80
Vitamin A Palmitate 0.010% Vitamin ETPGS0.025% inside Liposomes	0.0100 %	0.0040 %	60
Vitamin A Palmitate 0.010% Vitamin ETPGS 0.025% in Liposomes plus Pycnogenols 0.017% in water phase	0.0100 %	0.0050%	50
Vitamin A Palmitate 0.010% VitaminETPGS0.025% inside Liposomes plus Vitamin B12 0.0035% in water phase	0.0100 %	0.0045 %	55
Vitamin A Palmitate 0.010% + Vitamin E TPGS 0.025% inside Liposomes plus Pycnogenol™ 0.017% + Vitamin B12 0.0035% in	0.0100 %	0.0065 %	35

water phase			
-------------	--	--	--

*Irradiation power (intensity at different wave lengths)), see Reference (12).

- 200 nm 60mWatt
- 5 • 250 nm 90 mWatt
- 300 nm 125 mWatt
- 350 nm 137 mWatt
- 400 nm 118 mWatt

10 Such results demonstrate a shield effect against UVA/UVB insult.

Thus the Vitamin A Palmitate is protected by:

- Liposomes containing Vitamin E TPGS as such
- the Vitamin A Palmitate is protected by:
- 15 - Vitamin ETPGS inside the liposomes structure, and
- Pycnogenols, Vitamin B12 out side the liposomes, inside the water phase

The evaluation of degradation of Vitamin A Palmitate is only simple (trivial) tool to highlight
20 such protection, in the other hand this shield effect can be exerted to ocular surface (Reference 12) with evident advantage for patients suffering of dry eye syndrome or people that have to work for long time with light emitting device like computer screen

25 **Final conclusions**

- The activity, above described, explains how to produce, at industrial scale, an eye drops solution composed of liposomes built with not hydrogenated phospholipids containing Linseed oil, Vitamin A

Palmitate, Vitamin E TPGS, and in water phase Vitamin B12 and Pycnogenols.

- This liposomal eye drops solution has to be sterilized by filtration at 0.2 micron, because the
5 steam sterilization (121 C for 15 minutes at 1 atm) destroys all components of liposomes.

- To achieve such result the liposomal eyes drop solution contains liposomes built with not hydrogenated phospholipids containing Vitamin E TPGS
10 that for its specific structure improves the filterability of liposomes, but this improvement it is not enough to have a satisfying filtration procedure to sterilize liposomal eyes drops.

- To achieve such result the liposomal eyes drops
15 solution contains a specific and peculiar system composed of 2-Amino-2(hydroxymethyl)propane-1,3-diol, that acts as salt forming agent for Pycnogenols (sparkly water soluble), and borate buffer.

- The liposomal eyes drops exerts a shield effect
20 against UVA UVB rays (UVA 315-400 nm - UVB 315 -280), such unexpected property is linked primarily to liposomes (plus Vitamin E TPGS) and secondarily to Vitamin B12 and Pycnogenols in water phase.

25 **Process for preparation of the Eyes Drop Solution**

According to another aspect of the invention, the Applicant has developed a process for the preparation of liposomal eye drops solution for use in the treatment of Dry eye syndrome comprising the following
30 three steps:

First step:

Preparation of Liposomes carrying Lipophilic substances

1) Solubilize all lipophilic ingredients, Not Hydrogenated Phospholipids, Linseed oil, Vitamin A
5 Palmitate plus Vitamin E TPGS vitamin by a solvent usually Ethanol;

2) The solvent is removed under vacuum to obtain a dry powder;

3) The powder is dispersed in borate buffer and
10 mixed by a mechanical mixer, a solution of large liposomes is obtained, that could be defined as Pro liposomes;

4) The solution of such large liposomes is then extruded at high pressure, in a range of 600/1000 bar;

15 5) The extrusion procedure at High pressure is repeated several times * 4/7* to obtain liposomes of size less than 200 nm.

In a preferred embodiment 100 liters of Liposomes
20 Solution is prepared with the following Formula:

FORMULA FOR LIPOPHILIC PHASE

Ingredients	% w/w
Phospholipid S80	1.00
Linseed Oil inside liposomes	0.100
Vitamin A palmitate inside liposomes	0.020
Vitamin E TPGS inside liposomes	0.050
Boric Acid	0.775
Sodium Tetraborate Decahydrate	0.060
Distilled Water	100
Ph	7,1-7.4
Osmolality mMOs/kg	275 -290

Second step:

**Preparation of Water Solution containing
Hydrophilic Substances**

5

- 6) Solubilize in distilled water Pycnogenols,
Tris, Vitamin B12, Hyaluronic Acid and Borate buffer;
7) A clear and red colored solution is obtained.

10

In a preferred embodiment 100 liters of Water
solution is prepared with the following Formula:

FORMULA FOR HYDROPHILIC PHASE

15

Ingredients	% w/w
Pycnogenol™ outside liposomes	0.034
Tris (2-Amino-2 (hydroxymethyl) propane-1,3-diol	0.6-0.4
Vitamin B12 outside liposomes	0.0070
Hyaluronic sodium salt (1.5-1.7 MDa) outside liposomes	0.300
Boric Acid	0.775
Sodium Tetraborate Decahydrate	0.060
Sodium Chloride	0.4-0.3
Distilled Water	100
Ph	7.1-7.4
Osmolality mMOs/kg	275 -290

Third step:

Preparation of Final Sterile Eyes Drops Solution

- 20 8) Liposomes solution (100 liters), prepared at
First step, is added to water colored Solution (100
liters), prepared at second step, obtaining a Final

Standard Eyes Drop Solution, sterilized by filtration at 0.2 micron filter, with the following formula:

5

STANDARD STERILE FORMULATION

FORMULA F

Phospholipid S80	0.500
Linseed Oil inside liposomes	0.050
Vitamin A palmitate inside liposomes	0.010
Vitamin E TPGS inside liposomes	0.025
Pycnogenol™ outside liposomes	0.017
Tris (2-Amino-2(hydroxymethyl)propane-1,3-diol	0.3-0.2
Vitamin B12 outside liposomes	0.0035
Hyaluronic sodium salt (1.5-1.7 MDa) outside liposomes	0.150
Boric Acid	0.775
Sodium Tetraborate Decahydrate	0.060
Sodium Chloride	0.2-0.15
Distilled Water	100
Sterilization by filtration at 0.2 micron	Yes
Ph	7.1-7.4
Osmolality mMOs/kg	275 -290

- In a preferred embodiment 200 liters of Standard EYES Drop Solution is prepared with the above Standard
10 Formula F.


Modification of the above described modes for carrying out the invention that are obvious to person of skill in the art to which the invention pertains are
15 intended to be within the field of the invention as defined herein.

BIBLIOGRAPHY

- 1) Anti-inflammatory, analgesic and antipyretic activities of *Linum usitatissimum* L. (flaxseed/linseed) fixed oil.
- 5 Kaithwas G¹, Mukherjee A, Chaurasia AK, Majumdar DK.
2) Ocul Surf. 2009 Oct;7(4):176-85.
Antioxidant defenses in the ocular surface.
Chen Y¹, Mehta G, Vasiliou V.
3) Are Phospholipids the Critical Ingredient?.
- 10 Donald Korb, O.D., and Ralph Stone, Ph.D.
4) The effects of pycnogenol on antioxidant enzymes in a mouse model of ozone exposure
Min-Sung Lee,¹ Kuk-Young Moon,¹ Da-Jeong Bae,¹ Moo-Kyun Park,² and An-Soo Jang¹
- 15 5) Vitamin B12 deficiency evaluation and treatment in severe dry eye disease with neuropathic ocular pain.
Graefes Arch Clin Exp Ophthalmol. 2017 Jun;255(6):1173-1177. doi: 10.1007/s00417-017-3632-y. Epub 2017 Mar 15.
Ozen S¹, Ozer MA², Akdemir MO³.
- 20 6) Arch Biochem Biophys. 1996 Feb 1;326(1):57-63.
Synergistic interactions between vitamin A and vitamin E against lipid peroxidation in phosphatidylcholine liposomes.
Tesoriere L¹, Bongiorno A, Pintaudi AM, D'Anna R, D'Arpa D, Livrea MA.
- 25 7) Vitamin E TPGS as a Molecular Biomaterial for Drug Delivery
Biomaterials 33(19):4889-906·April 2012 with 203 Reads
DOI: 10.1016/j.biomaterials.2012.03.046 Source: PubMed
- 30 8) Using Tocophersolan for Drug Delivery: A natural vitamin E derivative is an innovative excipient

Jan 02, 2015 By Yves Robin Pharmaceutical Technology
Volume 39, Issue 1

- 9) Pucker AD, Ng SM, Nichols JJ (2016). "Over the counter (OTC) artificial tear drops for dry eye syndrome". Cochrane Database Syst Rev.2: CD009729.
- 5
- 10) UltraPure™ Buffer-Saturated Phenol Catalog number: 15513047
- 11) Ketorolac Trometamin salt anti inflammatory drug



ID CAS: 74103-06-3

Molar mass: 255,27 g/mol

12) VIII. Évfolyam 3. szám - 2013. szeptember

- 15 Kolonics Gábor THE EXAMINATION OF UV ABSORPTION OF
POLYPHENOLS (NATURAL SUBSTANCE)

CLAIMS

1) An aqueous eye drops solution for use in the treatment of dry eye syndrome comprising liposomes having a size of less than 200nm, Vitamin B12 and Pinus Pinaster bark extract, wherein:

said liposomes comprise non hydrogenated phospholipids containing Linseed oil, Vitamin A Palmitate, Vitamin E TPGS, and the solution further comprises a system composed of 2-Amino-2(hydroxymethyl)propane-1,3-diol or tris 2-Amino-2(hydroxymethyl)propane-1,3-diol, and buffer pH regulator, the system acting as salt forming agent of the Pinus Pinaster bark extract, to increase the solubility of said Pinus Pinaster bark extract.

2) The aqueous eye drops solution according to claim 1, characterized in that it is sterilized by filtration at 0.2 µm.

3) The aqueous eye drops solution according claim 1, wherein the aqueous eye drops solution comprising liposomes exert a shield effect against UVA UVB rays.

4) An aqueous eye drops solution having the following composition, based on total weight:

Ingredients	Amount in percent by weight
Phospholipid S80	0.250-0.750
Linseed Oil	0.025-0.075
Vitamin A palmitate	0.005-0.015
Vitamin E TPGS inside liposomes	0.0125-0.0375
Pinus Pinaster bark extract	0.0085-0.0255
Tris (2-Amino-2(hydroxymethyl)propane-1,3-diol	0.3-0.2-0.4-0.3

Vitamin B12	0.00175- 0.00525
Hyaluronic sodium salt (1.5-1.7 MDa) outside liposomes	0.0750- 0.225
Boric Acid	0.775
Sodium Tetraborate Decahydrate	0.0600
Sodium Chloride	0.2-0,15
Distilled Water	100
Sterilization by filtration at 0.2 µm	Yes
pH	7,1-7.4
Osmolality mMOs/kg	275-290

5) An aqueous eye drops solution having the following percent composition, based on total weight:

Ingredients	Amount in percent by weight
Phospholipid S80	0.500
Linseed Oil	0.050
Vitamin A palmitate	0.010
Pinus Pinaster bark extract	0.017
Tris (2-Amino-2 (hydroxymethyl) propane-1,3-diol	0.3-0.2
Vitamin B12	0.0035
Hyaluronic sodium salt (1.5-1.7 MDa) outside liposomes	0.150
Vitamin E TPGS outside liposomes	0.025
Boric Acid	0.775
Sodium Tetraborate Decahydrate	0.060
Sodium Chloride	0.2-0,15
Distilled Water	100
Sterilization by filtration at 0.2 µm	Yes
pH	7,1-7.4
Osmolality mMOs/kg	275 -290

6) Process for preparation of an eye drops solution for use in the treatment of dry eye syndrome, comprising the following steps:

first step:

preparation of a lipophilic phase:

- solubilizing all lipophilic ingredients comprising linseed oil, Vitamin A Palmitate plus Vitamin E TPGS, and non hydrogenated phospholipids, by a solvent,
- removing the solvent under vacuum to obtain a dry powder,
- dispersing the powder in borate buffer and mixing by a mechanical mixer, such that a solution of agglomerates of liposomes is obtained;
- extruding the solution of such agglomerates of liposomes at high pressure, between 600/1000 bar;
- repeating the extrusion procedure at high pressure between 4 and 7 times, to obtain liposomes of a size less than 200 nm;

second step:

preparation of a hydrophilic phase:

- solubilizing in distilled water Pinus Pinaster bark extract, Tris, Vitamin B12, Hyaluronic Acid and a system composed of 2-Amino-2(hydroxymethyl)propane-1,3-diol or tris 2-Amino-2(hydroxymethyl)propane-1,3-diol, and a borate buffer;

wherein a concentration of lipophilic substances in the first step and a concentration of hydrophilic substances in the second step are such as to permit, added each other in volume 1:1, to get the solution with a desired concentration; thereby obtaining a clear red colored solution;

third step:

preparation of a final eye drops solution being sterile:

adding a first amount of the lipophilic phase, prepared at first step, to a second amount of the hydrophilic phase, prepared at second step, obtaining a third amount being the sum of the first

amount and the second amount thereby obtaining the clear red colored solution of a standard eye drop solution, and

sterilizing the standard eye drop solution by filtration at 0.2 μm filter to obtain the final eye drops solution.

7) The aqueous eye drops solution according to any one of claims 1 to 5 for use in the treatment of dry eye syndrome.

8) The aqueous eye drops solution obtained by the process of claim 6 for use in the treatment of dry eye syndrome as shield against UVA/UVB rays.

9) Use of the aqueous eye drops solution as defined in any one of claims 1 to 5 in the treatment of dry eye syndrome.

10) Use of an aqueous eye drops solution obtained by the process of claim 6 for use in the treatment of dry eye syndrome as shield against UVA/UVB rays.